MicroRNAs in oncology: a translational perspective in the era of AI.
1/5 보강
Over the past three decades, knowledge of microRNA (miRNA) biology has advanced from the initial discovery of their regulatory functions to the finding of abnormal activity in leukaemias, and then to
APA
Jurj A, Dragomir MP, et al. (2026). MicroRNAs in oncology: a translational perspective in the era of AI.. Nature reviews. Clinical oncology, 23(4), 239-259. https://doi.org/10.1038/s41571-025-01114-x
MLA
Jurj A, et al.. "MicroRNAs in oncology: a translational perspective in the era of AI.." Nature reviews. Clinical oncology, vol. 23, no. 4, 2026, pp. 239-259.
PMID
41540122 ↗
Abstract 한글 요약
Over the past three decades, knowledge of microRNA (miRNA) biology has advanced from the initial discovery of their regulatory functions to the finding of abnormal activity in leukaemias, and then to a comprehensive understanding of the roles of miRNAs in both normal physiology and most diseases, with cancer being extensively studied. miRNA dysregulation contributes to tumorigenesis, with certain miRNAs acting as either tumour suppressors or oncogenic factors in a context-dependent manner. A subset of miRNAs have shown promise as tumour biomarkers and therapeutic targets in preclinical studies, with several miRNA-based diagnostic tools and treatments progressing to clinical trials. Artificial intelligence (AI) and machine learning techniques began to be introduced into cancer research and oncology a decade ago and are now on the verge of revolutionizing biomarker identification and clinical trials. In this Review, we highlight important roles of miRNAs in cancer biology and their potential as diagnostic tools and therapeutic targets. In particular, we discuss emerging challenges and opportunities presented by AI-driven data analysis and combinatorial strategies, and how advances in these areas have addressed previous doubts on the clinical translation of miRNA-based biomarkers and therapeutics.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.